Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia

DOI Web Site 被引用文献4件
  • Xueyan Chen
    Xueyan Chen, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Janis L. Abkowitz, and Elihu H. Estey, University of Washington; and Hu Xie, Roland B. Walter, John M. Pagel, Pamela S. Becker, Vicky K. Sandhu, Frederick R. Appelbaum, and Elihu H. Estey, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Hu Xie
    Xueyan Chen, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Janis L. Abkowitz, and Elihu H. Estey, University of Washington; and Hu Xie, Roland B. Walter, John M. Pagel, Pamela S. Becker, Vicky K. Sandhu, Frederick R. Appelbaum, and Elihu H. Estey, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Brent L. Wood
    Xueyan Chen, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Janis L. Abkowitz, and Elihu H. Estey, University of Washington; and Hu Xie, Roland B. Walter, John M. Pagel, Pamela S. Becker, Vicky K. Sandhu, Frederick R. Appelbaum, and Elihu H. Estey, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Roland B. Walter
    Xueyan Chen, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Janis L. Abkowitz, and Elihu H. Estey, University of Washington; and Hu Xie, Roland B. Walter, John M. Pagel, Pamela S. Becker, Vicky K. Sandhu, Frederick R. Appelbaum, and Elihu H. Estey, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • John M. Pagel
    Xueyan Chen, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Janis L. Abkowitz, and Elihu H. Estey, University of Washington; and Hu Xie, Roland B. Walter, John M. Pagel, Pamela S. Becker, Vicky K. Sandhu, Frederick R. Appelbaum, and Elihu H. Estey, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Pamela S. Becker
    Xueyan Chen, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Janis L. Abkowitz, and Elihu H. Estey, University of Washington; and Hu Xie, Roland B. Walter, John M. Pagel, Pamela S. Becker, Vicky K. Sandhu, Frederick R. Appelbaum, and Elihu H. Estey, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Vicky K. Sandhu
    Xueyan Chen, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Janis L. Abkowitz, and Elihu H. Estey, University of Washington; and Hu Xie, Roland B. Walter, John M. Pagel, Pamela S. Becker, Vicky K. Sandhu, Frederick R. Appelbaum, and Elihu H. Estey, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Janis L. Abkowitz
    Xueyan Chen, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Janis L. Abkowitz, and Elihu H. Estey, University of Washington; and Hu Xie, Roland B. Walter, John M. Pagel, Pamela S. Becker, Vicky K. Sandhu, Frederick R. Appelbaum, and Elihu H. Estey, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Frederick R. Appelbaum
    Xueyan Chen, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Janis L. Abkowitz, and Elihu H. Estey, University of Washington; and Hu Xie, Roland B. Walter, John M. Pagel, Pamela S. Becker, Vicky K. Sandhu, Frederick R. Appelbaum, and Elihu H. Estey, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Elihu H. Estey
    Xueyan Chen, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Janis L. Abkowitz, and Elihu H. Estey, University of Washington; and Hu Xie, Roland B. Walter, John M. Pagel, Pamela S. Becker, Vicky K. Sandhu, Frederick R. Appelbaum, and Elihu H. Estey, Fred Hutchinson Cancer Research Center, Seattle, WA.

説明

<jats:sec><jats:title>Purpose</jats:title><jats:p> Both presence of minimal residual disease (MRD) and achievement of complete remission (CR) with incomplete platelet recovery (CRp) rather than CR after induction therapy predict relapse in acute myeloid leukemia (AML). These results suggest a correlation between response (peripheral count recovery) and MRD at the time of morphologic remission. Here we examine this hypothesis and whether MRD and response provide independent prognostic information after accounting for other relevant covariates. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We retrospectively analyzed data from 245 adults with AML who achieved CR, CRp, or CR with incomplete blood count recovery (CRi) after induction therapy. Bone marrow samples were collected on or closest to the first date of blood count recovery, and MRD was determined by 10-color multiparameter flow cytometry. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> The 71.0% of patients who achieved CR had MRD less frequently and had lower levels of MRD than the 19.6% of patients achieving CRp and 9.4% achieving CRi. Although pretreatment covariates such as cytogenetics, monosomal karyotype, relapsed or refractory rather than newly diagnosed AML, and FLT3 internal tandem duplication were associated with relapse, their prognostic effect was much lower once MRD and response were taken into account, the univariable statistical effect of which was not materially affected by inclusion of pretreatment covariates. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Our data indicate that post-therapy parameters including MRD status and response are important independent prognostic factors for outcome in patients with AML achieving remission. MRD status and type of response (CR v CRp or CRi) should play important, and perhaps dominant, roles in planning postinduction therapy. </jats:p></jats:sec>

収録刊行物

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ